FDA Releases Draft Guidance on Cancer Clinical Trial Eligibility Criteria for Brain Metastases

Summary

The US Food and Drug Administration (FDA) has released a draft guidance for the pharmaceutical industry on cancer clinical trial eligibility criteria, specifically addressing the inclusion of patients with brain metastases. The guidance aims to improve the representativeness of trial populations and enhance the assessment of investigational drugs.